Now Approved in the U.S.
Our Science and Technology
Rooted in a Deep Understanding of Genetics
The genetic basis of human disease continues to inspire our science and technology as we expand to new therapeutic approaches, while our industry-leading chemistry helps us target the right medicine to the right disease – providing a rich source for future breakthroughs and transformative impact.
WHO WE ARE
Ionis unites groundbreaking science and technology with relentless passion to discover and deliver medicines that enable better futures for people living with serious diseases.
Our commitment to changing lives is a calling that pushes us to deliver the next solution for patients and those who care for them.
We have set our sights on providing new solutions across the spectrum of diseases, from common intractable neurologic conditions to cardiometabolic disorders and select areas of high patient needs.
We push beyond the impossible to unleash the potential of patients – and those who care for them – enabling them to make their own impact on the world.
We believe operating responsibly and sustainably creates long-term value and a positive impact for our company, stakeholders, patients, communities and the broader world.
JOIN OUR TEAM
Seizing the Moment to Unlock the Potential of RNA- and DNA-Targeted Medicines
If you’re driven to deliver on the promise of groundbreaking medicines that empower patients and caregivers to make their own impact on the world, come join us.
LATEST NEWS FEED
Ionis to host expert panel discussion on sHTG
– Webinar scheduled for Monday, April 14 at 11:00 a.m. ET – CARLSBAD, Calif. --(BUSINESS WIRE)--Apr. 3, 2025-- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it will host a webinar on Monday, April 14 th at 11:00 a.m. ET focused on the risks, clinical presentation and significant unmet
Ionis to present at upcoming investor conferences
CARLSBAD, Calif. --(BUSINESS WIRE)--Mar. 31, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 24 th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 Bank of America 2025
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
– Agreement enables olezarsen to reach people living with conditions associated with elevated triglycerides across the world – – Ionis will continue to independently commercialize TRYNGOLZA™ (olezarsen) in the U.S. – CARLSBAD, Calif. --(BUSINESS WIRE)--Mar. 26, 2025-- Ionis Pharmaceuticals, Inc.
Ionis to host expert panel discussion on sHTG
– Webinar scheduled for Monday, April 14 at 11:00 a.m. ET – CARLSBAD, Calif. --(BUSINESS WIRE)--Apr. 3, 2025-- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it will host a webinar on Monday, April 14 th at 11:00 a.m. ET focused on the risks, clinical presentation and significant unmet
Ionis to present at upcoming investor conferences
CARLSBAD, Calif. --(BUSINESS WIRE)--Mar. 31, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 24 th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 Bank of America 2025
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
– Agreement enables olezarsen to reach people living with conditions associated with elevated triglycerides across the world – – Ionis will continue to independently commercialize TRYNGOLZA™ (olezarsen) in the U.S. – CARLSBAD, Calif. --(BUSINESS WIRE)--Mar. 26, 2025-- Ionis Pharmaceuticals, Inc.
Sign Up for News Alerts
For the latest on Ionis news and developments
– Webinar scheduled for Monday, April 14 at 11:00 a.m. ET – CARLSBAD, Calif. --(BUSINESS WIRE)--Apr. 3, 2025-- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it will host a webinar on Monday, April 14 th at 11:00 a.m. ET focused on the risks, clinical presentation and significant unmet
CARLSBAD, Calif. --(BUSINESS WIRE)--Mar. 31, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 24 th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 Bank of America 2025
– Agreement enables olezarsen to reach people living with conditions associated with elevated triglycerides across the world – – Ionis will continue to independently commercialize TRYNGOLZA™ (olezarsen) in the U.S. – CARLSBAD, Calif. --(BUSINESS WIRE)--Mar. 26, 2025-- Ionis Pharmaceuticals, Inc.
Click here to read an important notice about a cybersecurity incident relating to services provided to WEX Health (an Ionis employee benefits plan administrator).